Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2022 09:00 ET | Source: GeoVax, Inc.

GeoVax Announces Issuance of Malaria Vaccine Patent

GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs,...
April 19, 2022 09:00 ET | Source: GeoVax, Inc.

GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update

Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time ATLANTA, GA, April 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
April 18, 2022 17:52 ET | Source: GeoVax, Inc.

CORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option

Singapore, April 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire--In a release issued under the same headline on Monday, April 18th at 1:55 ET by GeoVax, Inc., please note that the release was...
April 12, 2022 09:00 ET | Source: GeoVax, Inc.

GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress

Company’s COVID-19 Vaccine Candidate GEO-CM04S1 Continues to Advance in COVID-19 Phase 2 Clinical Trials While the Experimental Universal Vaccine Candidate GEO-CM02 Demonstrated Single-Dose, 100%...
March 22, 2022 09:00 ET | Source: GeoVax, Inc.

GeoVax Announces Issuance of Cancer Vaccine Patent

IND-Enabling Studies Underway for MVA-VLP-MUC1 Vaccine Candidate Atlanta, GA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
March 21, 2022 09:00 ET | Source: GeoVax, Inc.

GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022

Presentation to Focus on GEO-CM02 Being Developed as aUniversal Vaccine to Address Evolving SARS-CoV-2 Variants ATLANTA, GA, March 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
March 16, 2022 09:00 ET | Source: GeoVax, Inc.

GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference

Chairman & CEO David Dodd to Present Corporate UpdateCSO Mark Newman, PhD to Participate in Fireside Chatwith Maxim Analyst Jason McCarthy, PhD ATLANTA, GA , March 16, 2022 (GLOBE NEWSWIRE)...
March 14, 2022 09:00 ET | Source: GeoVax, Inc.

GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials

Comparative Trial Against Pfizer/BioNTech Vaccine Among Immunocompromised PatientsBooster to Pfizer/BioNTech or Moderna Vaccines Among Healthy PatientsATLANTA, GA, March 14, 2022 (GLOBE NEWSWIRE) --...
March 10, 2022 09:00 ET | Source: GeoVax, Inc.

Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2

The investigational vaccine is now being used in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers LOS ANGELES and ATLANTA, March 10, 2022 (GLOBE NEWSWIRE)...
March 09, 2022 16:00 ET | Source: GeoVax, Inc.

GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, March 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...